Featured Research

from universities, journals, and other organizations

One-fifth Of Rheumatoid Arthritis Patients In Drug-free Remission Following A Specific Treatment

Date:
June 20, 2007
Source:
European League Against Rheumatism
Summary:
Early treatment with a combination of methotrexate and infliximab may be effective as remission induction therapy and alter the course of early rheumatoid arthritis, according to new research.

Early treatment with a combination of methotrexate and infliximab may be effective as remission induction therapy and alter the course of early rheumatoid arthritis (RA), according to data presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

At four year follow up, over half (51%) of the patients who started treatment with a combination of methotrexate and infliximab in the BeSt ('Behandel--Strategieλn' or 'treatment strategies') trial had been able to discontinue treatment with infliximab and maintained a good response (Disease Activity Score (DAS) d2.4). 41 patients were still taking methotrexate monotherapy at trial end. Almost one in five (17%) of patients had reached clinical remission (DAS <1.6), with minimal joint damage progression, and were no longer receiving any anti-rheumatic drugs,

Study leader Dr Cornelia F. Allaart commented: "Our findings indicate that clinical remission from RA is achievable provided effective treatment - such as the infliximab methotrexate combination we used in the fourth arm of this study - is administered early in the course of the disease."

508 patients with newly diagnosed, untreated rheumatoid arthritis from The Netherlands were enrolled in the BeSt trial which compared four different treatment strategies in patients with early or recent onset rheumatoid arthritis (RA). 120 patients were randomized to arm 4 and started initial combination therapy with methotrexate and infliximab. At enrolment, all patients had active disease with a disease activity score (DAS) of 4.3, and 64% of patients were classified as rheumatoid factor positive.

Patients received infliximab 3mg/kg plus methotrexate 25mg/week at start of the trial. Dosages of infliximab were altered in a responsive manner according to the DAS throughout the trial.

Disease progression over the course of the trial was ascertained by including the Health Assessment Questionairre (HAQ) as measure for daily functioning, and the van der Heijde modification of the Sharp score (SHS) to assess damage on hand and feet x-rays at initiation of the trial and at 4 years.

The lowest SHS was reported in patients who had reached a stable DAS of <1.6 or clinical remission. Predictably, the highest rate of SHS progression was reported in patients who had failed on the combination of methotrexate and infliximab.

The patients who had reached drug-free remission,had had active RA at baseline (DAS 4.1), 45% were rheumatoid factor positive and 74% had pre-existing erosions.

Of the 120 patients treated with initial methotrexate and infliximab, 30 patients failed on that therapy and proceeded to next pre-specified treatment steps.


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "One-fifth Of Rheumatoid Arthritis Patients In Drug-free Remission Following A Specific Treatment." ScienceDaily. ScienceDaily, 20 June 2007. <www.sciencedaily.com/releases/2007/06/070614154858.htm>.
European League Against Rheumatism. (2007, June 20). One-fifth Of Rheumatoid Arthritis Patients In Drug-free Remission Following A Specific Treatment. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2007/06/070614154858.htm
European League Against Rheumatism. "One-fifth Of Rheumatoid Arthritis Patients In Drug-free Remission Following A Specific Treatment." ScienceDaily. www.sciencedaily.com/releases/2007/06/070614154858.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) — A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) — Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com
West Africa Gripped by Deadly Ebola Outbreak

West Africa Gripped by Deadly Ebola Outbreak

AFP (July 28, 2014) — The worst-ever outbreak of the deadly Ebola epidemic grips west Africa, killing hundreds. Duration: 00:48 Video provided by AFP
Powered by NewsLook.com
Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) — A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins